Log in to save to my catalogue

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy...

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2910195541

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

About this item

Full title

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Cancer Immunology, Immunotherapy, 2024-01, Vol.73 (1), p.4-4, Article 4

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Introduction
Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). Compared with immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy can increase immune-related toxicity instead of prolonging survival. This st...

Alternative Titles

Full title

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2910195541

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2910195541

Other Identifiers

ISSN

0340-7004

E-ISSN

1432-0851

DOI

10.1007/s00262-023-03583-4

How to access this item